Market news

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 22.21% on an annualized basis producing an average annual return of 34.23%. Currently, McKesson has a market capitalization of $102.91 billion.

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

IRVING, Texas, September 23, 2026--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

McKesson recently raised its full-year EPS guidance, projecting approximately 13%–15% growth (15%–17% excluding certain prior-year items), and outlined plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO targeted for the second half of 2027, alongside a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. This combination of upgraded earnings expectations, portfolio reshaping around...

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl

McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

The company, which distributes medicines and medical devices to hospitals and healthcare practices across the U.S., said it was hacked and expects intermittent service degradation.

McKesson Corporation (NYSE:MCK) has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-growth businesses. Precision Medicine provides clinical research, laboratory testing, and commercialization services to biotechnology and pharmaceutical companies developing and launching new medicines. McKesson plans to integrate the company into its […]

McKesson (NYSE:MCK) announced an agreement to acquire Precision Medicine Group to expand its oncology and clinical research services. The deal is aimed at deepening McKesson's role in personalized medicine and specialty care, particularly in oncology and biopharma clinical trial support. The acquisition is expected to reshape McKesson's service mix across oncology practices, biopharma partners and clinical research organizations. For readers looking beyond McKesson to other potential...

MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.

McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services.

The drug distributor will fold the clinical research and biopharma commercialization firm into its oncology unit once the deal closes

MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.

McKesson (MCK) has agreed to acquire Precision Medicine in a transaction worth roughly $2.25 billion

drug distributor McKesson ‌said on Tuesday ‌it would buy clinical ​research and biopharma commercialization services provider Precision Medicine Group in ‌a ⁠deal valued at about $2. The acquisition ⁠will expand McKeeson's clinical research ​and commercialization ​capabilities ​and broaden its ‌offerings to biopharma customers.

IRVING, Texas, August 25, 2026--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC ("Precision Medicine Group"), a global provider of clinical research and biopharma commercialization services.

McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.